|
Synonyms: M70 | NGM-282 | NGM282
Compound class:
Peptide or derivative
Comment: Aldafermin (NGM282) is a recombinant, engineered analogue of FGF-19 (FGF19-mimetic) that was developed by NGM Biopharmaceuticals. Acting via the FGFR4-β-Klotho (KLB) receptor complex, aldafermin acts to suppress cholesterol 7α-hydroxylase (CYP7A1), the first and rate-limiting enzyme for bile acids biosynthesis.
|
| No information available. |
Summary of Clinical Use  |
| Aldafermin (NGM282) was advanced to clinical evaliuation for antifibrotic activity as a mechanism to treat nonalcoholic steatohepatitis (NASH) and other cholestatic liver diseases. NGM Biopharmaceuticals decided not to advance aldafermin to Phase 3 for NASH, following a failure to demonstrate clinical benefit in Phase 2b. |
| Clinical Trials | |||||
| Clinical Trial ID | Title | Type | Source | Comment | References |
| NCT02704364 | Phase 2 Study of NGM282 in Patients With Primary Sclerosing Cholangitis | Phase 2 Interventional | NGM Biopharmaceuticals, Inc | 2 | |
| NCT02443116 | Study of NGM282 in Patients With Nonalcoholic Steatohepatitis (NASH) | Phase 2 Interventional | NGM Biopharmaceuticals, Inc | 1-2 | |
